Drugs / ABX-1431
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03447756 | Oct 2017 → May 2019 | diabetic polyneuropathy, neuropathy, small fiber, postherpetic neuralgia | Abide Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03138421 | Aug 2017 → Jul 2018 | multiple sclerosis, neuromyelitis optica, transverse myelitis | Abide Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03058562 | Feb → Oct 2017 | Tourette syndrome, chronic tic disorder | Abide Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02929264 | Dec 2016 → Mar 2018 | — | Abide Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02875678 | Nov 2016 → Aug 2017 | dyspepsia | Abide Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03625453 | Oct 2018 → Jan 2020 | Tourette syndrome | Abide Therapeutics | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABX-1431 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03447756 ↗ |
| Known as | Lu AG06466 | “Modulation of the endocannabinoid system via monoacylglycerol lipase inhibition with Lu AG06466 (formerly known as ABX-1431) has previously been shown to reduce tics in...” PMID 34117788 ↗ Jun 2021 |
| Action | Inhibit | “ABX-1431 is a potent and selective, orally available, irreversible inhibitor of monoacylglycerol lipase” NCT03625453 ↗1“Monoglyceride lipase inhibitor” CHEMBL3945728 ↗ |
| Modality | Small molecule | — CHEMBL3945728 ↗ |
| Route | Oral | “One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients.” NCT03447756 ↗ |
| Target | MGLL | “Monoglyceride lipase inhibitor” CHEMBL3945728 ↗ |